Dabigatran may be a cost-effective alternative to warfarin for stroke prevention in atrial fibrillation

被引：0
|
作者：
不详
机构：
来源：
FORMULARY | 2011年 / 46卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：39 / 39
页数：1
相关论文
共 50 条
  • [31] A Comparative Analysis of Models Used to Evaluate the Cost-Effectiveness of Dabigatran Versus Warfarin for the Prevention of Stroke in Atrial Fibrillation
    Sorensen, Sonja V.
    Peng, Siyang
    Monz, Brigitta U.
    Bradley-Kennedy, Carole
    Kansal, Anuraag R.
    PHARMACOECONOMICS, 2013, 31 (07) : 589 - 604
  • [32] Dabigatran (Pradaxa) for Prevention of Stroke in Atrial Fibrillation
    Strohecker, Jennifer L.
    AMERICAN FAMILY PHYSICIAN, 2011, 84 (12) : 1397 - 1398
  • [33] A Comparative Analysis of Models Used to Evaluate the Cost-Effectiveness of Dabigatran Versus Warfarin for the Prevention of Stroke in Atrial Fibrillation
    Sonja V. Sorensen
    Siyang Peng
    Brigitta U. Monz
    Carole Bradley-Kennedy
    Anuraag R. Kansal
    PharmacoEconomics, 2013, 31 : 589 - 604
  • [34] Dabigatran etexilate: An alternative to warfarin for patients with nonvalvular atrial fibrillation
    Scott, Katie A.
    Amirehsani, Karen A.
    JOURNAL OF THE AMERICAN ASSOCIATION OF NURSE PRACTITIONERS, 2015, 27 (04) : 190 - 196
  • [35] Dabigatran or warfarin for the prevention of stroke in atrial fibrillation? A closer look at the RE-LY trial
    DiNicolantonio, James J.
    EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (08) : 1101 - 1111
  • [36] STROKE PROPHYLAXIS WITH WARFARIN AND DABIGATRAN FOR PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION - A COST ANALYSIS
    Ali, A. N.
    Bailey, C.
    Abdulhafiz, A. H.
    AGE AND AGEING, 2013, 42 : 31 - 31
  • [37] Efficacy and safety of dabigatran, rivaroxaban, and warfarin for stroke prevention in Chinese patients with atrial fibrillation: the Hong Kong Atrial Fibrillation Project
    Li, Wen-Hua
    Huang, Duo
    Chiang, Chern-En
    Lau, Chu-Pak
    Tse, Hung-Fat
    Chan, Esther W.
    Wong, Ian C. K.
    Lip, Gregory Y. H.
    Chan, Pak-Hei
    Siu, Chung-Wah
    CLINICAL CARDIOLOGY, 2017, 40 (04) : 222 - 229
  • [38] Cost-Effectiveness of Dabigatran versus Genotype-Guided Management of Warfarin Therapy for Stroke Prevention in Patients with Atrial Fibrillation
    You, Joyce H. S.
    Tsui, Kia K. N.
    Wong, Raymond S. M.
    Cheng, Gergory
    PLOS ONE, 2012, 7 (06):
  • [39] Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation: A Cost-Effectiveness Analysis
    Carla Rognoni
    Monia Marchetti
    Silvana Quaglini
    Nicola Lucio Liberato
    Clinical Drug Investigation, 2014, 34 : 9 - 17
  • [40] Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation: A Cost-Effectiveness Analysis
    Rognoni, Carla
    Marchetti, Monia
    Quaglini, Silvana
    Liberato, Nicola Lucio
    CLINICAL DRUG INVESTIGATION, 2014, 34 (01) : 9 - 17
12345